Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological Targets

Area of Science:

• Oncology
• Medicinal Chemistry
• Bioinformatics

Background:

• Cancer involves abnormal cell division and metastasis.
• Current cancer therapies face challenges like drug resistance, toxicity, and ineffectiveness.
• Targeting multiple cancer pathways offers a promising therapeutic strategy.

Purpose of the Study:

• To present a comprehensive review of heterocyclic compounds with multitarget anticancer properties.
• To compile data on synthetic and natural product-derived heterocyclic compounds.
• To document their inhibitory effects (IC50) and biological targets.

Main Methods:

• Literature review of omics, bioinformatics, and cheminformatics discoveries.
• Identification of drugs targeting key pathways like VEGF, FGF, PDGF, EGF, TP, and NY4.
• Compilation of data on heterocyclic compounds, their IC50 values, and inhibition targets.

Main Results:

• Heterocyclic compounds, from both synthetic and natural sources, show significant anticancer potential.
• These compounds exhibit multimodal activity by inhibiting multiple targets.
• Data on IC50 values and specific biological targets are provided for various compounds.

Conclusions:

• Heterocyclic compounds represent a valuable class of agents for multitarget cancer therapy.
• Their ability to inhibit multiple targets may overcome existing therapeutic limitations.
• This compendium serves as a resource for developing novel anticancer drugs.